Squamous Cell Carcinoma Clinical Trials in Boston, Massachusetts

4 studies are recruiting for squamous cell carcinoma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Tufts Medical Center, Boston, Massachusetts
    Locations
    8 in total
    Run by
    Neonc Technologies, Inc.

    See if you can join NCT06047379 on ClinicalTrials.gov

  2. Toripalimab With Chemotherapy for Sinus Cancer

    The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers. The names of the study drugs used in this …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT06940180 on ClinicalTrials.gov

  3. PDT For Induction Therapy For Head And Neck Cancer

    This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Massachusetts General Hospital

    See if you can join NCT07214987 on ClinicalTrials.gov

  4. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Locations
    9 in total
    Run by
    ImmVira Pharma Co. Ltd

    See if you can join NCT04370587 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.